One Of The Saddest Days Of My Life
I really hate losing. And I’ve just experienced an enormous failure. Words are really shitty tools but often times, that is the only weapon we have. I’ll explain this in today’s Radio Free Wall Street.
As vaccine demand falls, states are left with huge stockpile
https://youtu.be/eSIpGreQdOM
As demand for COVID-19 vaccines collapses in many areas of the U.S., states are scrambling to use stockpiles of doses before they expire and have to be added to the millions that have already gone to waste. From some of the least vaccinated states, like Indiana and North Dakota, to some of the most vaccinated states, like New Jersey and Vermont, public health departments are shuffling doses around in the hopes of finding providers that can use them. State health departments told The Associated Press they have tracked millions of doses that went to waste, including ones that expired, were in a multi-dose vial that couldn’t be used completely or had to be tossed for some other reason like temperature issues or broken vials. Nearly 1.5 million doses in Michigan, 1.45 million in North Carolina, 1 million in Illinois and almost 725,000 doses in Washington couldn’t be used. The percentage of wasted doses in California is only about 1.8%, but in a state that has received 84 million doses and administered more than 71 million of them, that equates to roughly 1.4 million doses. Providers there are asked to keep doses until they expire, then properly dispose of them, the California Department of Public Health said. The national rate of wasted doses is about 9.5% of the more than 687 million doses that have been delivered as of late February, the Centers for Disease Control and Prevention said Thursday. That equates to about 65 million doses. Continue reading “As vaccine demand falls, states are left with huge stockpile”
niclosamide in preventing the spread and the severity of COVID-19
https://youtu.be/Cjuu5Xw5AcE
A clinical research team at Tufts Medical Center and Tufts University today published the results of the first randomized placebo-controlled clinical trial of the effectiveness of niclosamide, an oral medication long-used worldwide for treatment of tapeworms, in COVID-19 patients. The study, sponsored by Tufts Clinical and Translational Science Institute (CTSI) and funded by the National Institutes of Health (NIH), found that niclosamide did not show a statistically significant reduction in the percentage of adult outpatients with mild to moderate COVID-19 still testing positive at day three, but provided signals of benefit that warrant further study in larger trials. As reported today in JAMA Network Open, Principal Investigator Harry Selker, MD, MSPH, Dean of Tufts CTSI and Executive Director of the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and colleagues, evaluated viral shedding of the virus that causes COVID-19, SARS-CoV-2. The study was conducted using an entirely remote clinical trial platform developed specifically for the study, to avoid requiring patients to have to visit the hospital and to support maintenance of participants’ self-quarantining. Approved by the US FDA for treatment of tapeworm infection in 1982, and used worldwide for 50 years in millions of adults, pregnant women, and children as young as two years old, niclosamide is included in the World Health Organization (WHO) list of essential medicines, as it is very safe, and it is affordable and widely available. The researchers hypothesized that its antiviral characteristics seen in basic research experiments might prevent the COVID-19 SARS-CoV-2 virus from entering and replicating in human cells. Niclosamide has demonstrated antiviral efficacy across multiple variants of SARS-CoV-2 in laboratory studies, suggesting that it may be effective against COVID-19, including all variants of the virus. Continue reading “niclosamide in preventing the spread and the severity of COVID-19”
Potential correlation, low vitamin D and increased risk of infection with SARS-CoV-2
People with low levels of Vitamin D may be more likely to catch coronavirus and die from COVID-19 infection, study suggests
- Study compared average vitamin D levels in a country with coronavirus mortality
- Found a link showing low vitamin D levels are associated with a higher death rate
- Researchers ‘believe they can advise vitamin D supplementation’ to protect against the coronavirus
A preliminary study has found tentative evidence suggesting low levels of vitamin D may make it more likely an individual will die after contracting coronavirus. The research compared average levels of vitamin D across 20 European countries with COVID-19 infection rate and mortality. It revealed a convincing correlation where countries with low vitamin D levels were also the countries with highest mortality and COVID-19 infection rates. NN: We have long recommended that you Vitamin UP. And the fact that vitamin D is a great immune system booster. We were so convinced that we had compounded our special supplement The CoronaVit that had the right combination of ingredients, in the right form to maximize absorption. So all I can say is take your vitamins.
Radio Free Wall Street
It’s Ugly And Getting Uglier
Putin is not crazy. Sanctions are a joke and Putin is making more money on energy than ever. Europe and the U.S. are not willing to stop him.
The new omicron BA2 mutation is more contagious and will be more infectious
- Danish scientists confirmed this week that the new subvariant can reinfect people who’ve previously had omicron, although it doesn’t appear to be all that common.
- They also agree that it’s more contagious than the original version of omicron, BA.1, which is still widely circulating around the world.
- But it’s surprisingly not driving a second wave of omicron infections. Globally, Covid cases have plunged 21% over the past week.
Continue reading “The new omicron BA2 mutation is more contagious and will be more infectious”
U.S. FDA considers approving a second COVID-19 booster shot
(Reuters) -U.S. health regulators are looking at authorizing a potential fourth dose of a COVID-19 vaccine in the fall, the Wall Street Journal reported on Saturday, citing sources familiar with the matter. The Food and Drug Administration has been reviewing data to authorize a second booster dose of the messenger RNA vaccines from Pfizer Inc and partner BioNTech SE and vaccines from Moderna Inc, the report added. The agency last month cut the interval to get a booster dose of COVID-19 vaccines from Pfizer and BioNTech as well as from Moderna, in a bid to provide better protection sooner against the Omicron variant. The planning is still in early stages, and authorization would depend on determinations as to whether the second booster should be authorized for all adults or particular age groups, and whether it should target the Omicron variant or be formulated differently, the report said. It added that no decision was final and that it could be necessary to make booster shots available earlier if a new variant appears. The United States reported 2,323 COVID-19 deaths on Friday, bringing the total count to 936,523. NN: It is settled business typical of these types of vaccines like the flue Jap the vaccine wears off very quickly. In the case of the covid vaccines studies show in 4 to 5 months protection drops dramatically Say you get your booster shot in March. That means your timing would be right to receive the modified to new variants that should be available in August or September. Thats when it looks like the new subvariant BA.2 starts infecting people in mass. For the record its a mistake to open things all the way. Have we not learned anything. Every time they open things up within 6 months another wave is upon us. The BA,2 variant is now dominate in South Africa, India, England and Denmark. A recent Denmark study finds its 30% more infectious than the current variant.an it infects more fully vaccinated people then any other variant. This is very early data.
Meet your new monster the BA.2 Omicron subvarient
https://youtu.be/PoxC0FQGqFQ
(CNN)The BA.2 virus — a subvariant of the Omicron coronavirus variant — isn’t just spreading faster than its distant cousin, it may also cause more severe disease and appears capable of thwarting some of the key weapons we have against Covid-19, new research suggests. New lab experiments from Japan show that BA.2 may have features that make it as capable of causing serious illness as older variants of Covid-19, including Delta. And like Omicron, it appears to largely escape the immunity created by vaccines. A booster shot restores protection, making illness after infection about 74% less likely. BA.2 is also resistant to some treatments, including sotrovimab, the monoclonal antibody that’s currently being used against Omicron. The findings were posted Wednesday as a preprint study on the bioRxiv server, before peer review. Normally, before a study is published in medical journal, it is scrutinized by independent experts. Preprints allow research to be shared more quickly, but they are posted before that additional layer of review.
Continue reading “Meet your new monster the BA.2 Omicron subvarient”
Worst yet to come Omicron is evading vaccines
Omicron is widely known to be more contagious than previous Covid strains. Scientists believe the worst of the virus may not yet be over. In a highly secure clean room at the University of NSW’s Kirby Institute, experts studied the strain at the beginning of Australia’s Omicron wave in mid-December and found out just how adept the variant is at evading vaccines. While the Delta variant was 60 per cent better at evading antibodies than the original virus found in Wuhan – even in the bodies of the double-vaxxed, Omicron was 16.5 times better at evading immunity – 10 times more than Delta. That explains why Omicron surged so quickly when it arrived in Australia – going from 110,000 active cases nationwide on Dec. 30 to 835,000 on Jan. 17. It has since eased significantly, with numbers dropping around 80 per cent since. But while the Omicron wave is subsiding across the globe, scientists believe new variants may continue to emerge for years – particularly in winter. Research from the Kirby Institute shows exactly how much more adept Omicron is at evading immunity via two vaccines or prior infection (pictured). A booster provides more protection Continue reading “Worst yet to come Omicron is evading vaccines”
Oklahoma Physicians Are Not Prohibited From Prescribing Off-Label Medicines to Fight COVID-19
The Attorney General’s office finds no legal basis for a state medical licensure board to discipline a licensed physician for exercising sound judgement and safely prescribing an FDA-approved drug – like ivermectin or hydroxychloroquine – for the off-label purpose of treating a patient with COVID-19 Attorney General John O’Connor I stand behind doctors who believe it is in their patients’ best interests to receive ivermectin and hydroxychloroquine Our healthcare professionals should have every tool available to combat COVID-19. Public safety demands this. Physicians who prescribe medications and follow the law should not fear disciplinary action for prescribing such drugs The Attorney General’s office neither condones nor condemns a specific course of treatment for COVID-19. Our office maintains that proper healthcare decisions are to be made between a patient and his or her physician, and the government should not interfere with their relationship. FDA position unchanged…